Pfizer’s Go-It-Alone Approach Nets $1.95bn COVID Vaccine Order From US Government

 
• By Cathy Kelly
Freeway
Pfizer/BioNTech Assuming All Risk For Vaccine Development, Production

More from Pricing Debate

More from Market Access